Michael Minogue - ABIOMED Chairman
Chairman
Mr. Michael R. Minogue is the Chairman of the Board, President, Chief Executive Officer of Abiomed, Inc. He has served as our Chief Executive Officer, President and a director since April 2004. In June 2005, he was appointed Chairman of our Board of Directors. Prior to joining us, Mr. Minogue had a twelveyear career at General Electric, or GE. Most recently, Mr. Minogue was Vice President and General Manager of Americas Sales and Marketing for GE Medical Systems Information Technology. From 1997 to 2004, Mr. Minogue held various positions at GE, including General Manager for the Global Positron Emission Technology Business, General Manager, Americas Cardiology IT Sales and General Manager, Global Installed Base. Prior to joining GE, Mr. Minogue served on active duty for four years as an infantry officer in the U.S. Army and received multiple awards. Mr. Minogue received his BS in Engineering Management from the United States Military Academy at West Point and his MBA from the University of Chicago. Mr. Minogue currently serves on the Board of Directors of the Advanced Medical Technology Association and also serves as a Manager on the Board of Managers of Bioventus LLC, a strategic partnership between EW Healthcare Partners and Smith Nephew plc, a global medical technology business based in the United Kingdom. Mr. Minogue is also the Chair of the Board of Directors of the Medical Device Innovation Consortium, a publicprivate partnership created with the objective of advancing medical device regulatory science, and a member of the Board of Directors of Insulet Corporationrationration, a medical device company focused on advancing the treatment of diabetes and other conditions through the use of a proprietary insulin pump. He was formerly on the Board of Directors of LifeCell Corporationrationration, which was acquired by Kinetic Concepts, Inc. in May 2008. since 2005.
Age | 56 |
Tenure | 19 years |
Phone | 978 777-8411 |
Web | www.abiomed.com |
ABIOMED Management Efficiency
The company has return on total asset (ROA) of 0.0955 % which means that it generated a profit of $0.0955 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1824 %, meaning that it created $0.1824 on every $100 dollars invested by stockholders. ABIOMED's management efficiency ratios could be used to measure how well ABIOMED manages its routine affairs as well as how well it operates its assets and liabilities.ABIOMED currently holds 10 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. ABIOMED has a current ratio of 7.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ABIOMED's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Found 9 records | CHAIRMAN Age | ||
Walter Johnsen | Acme United | 73 | |
Jerry Whitaker | Sealed Air | 70 | |
David Taylor | Procter Gamble | 62 | |
Jon Moeller | Procter Gamble | 60 | |
Stephen Hagge | CF Industries Holdings | 69 | |
Thomas Florsheim | Weyco Group | 66 | |
Edward Rosenfeld | Steven Madden | 48 | |
Stephen Furbacher | CF Industries Holdings | 72 | |
Douglas Baker | Ecolab Inc | 62 |
Management Performance
Return On Equity | 0.18 | |||
Return On Asset | 0.0955 |
ABIOMED Leadership Team
Elected by the shareholders, the ABIOMED's board of directors comprises two types of representatives: ABIOMED inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABIOMED. The board's role is to monitor ABIOMED's management team and ensure that shareholders' interests are well served. ABIOMED's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABIOMED's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Howley, VP and General Manager of Global Sales | ||
Michael Minogue, Chairman, CEO and President Member of Special Stock Option Committee and Member of Executive Committee | ||
Andrew Greenfield, Vice President - Healthcare Solutions | ||
Thorsten Siess, Ex Officer | ||
Ingrid Ward, Director Relations | ||
Matthew Plano, Ex Integration | ||
Todd Trapp, CFO, Vice President | ||
Sarah Karr, Communications Mang | ||
Marc Began, Gen VP | ||
David Weber, Scientific Advisor |
ABIOMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ABIOMED a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.18 | |||
Return On Asset | 0.0955 | |||
Profit Margin | 0.25 % | |||
Operating Margin | 0.23 % | |||
Current Valuation | 16.32 B | |||
Shares Outstanding | 45.09 M | |||
Shares Owned By Insiders | 2.02 % | |||
Shares Owned By Institutions | 97.00 % | |||
Number Of Shares Shorted | 753.62 K | |||
Price To Earning | 76.38 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in ABIOMED Stock
If you are still planning to invest in ABIOMED check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ABIOMED's history and understand the potential risks before investing.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |